THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this Document, or the action you should take, you are recommended to seek your own personal financial advice immediately from your stockbroker, bank manager, solicitor, accountant or other independent financial adviser authorised under the Financial Services and Markets Act 2000 (as amended) ("FSMA") if you are resident in the United Kingdom, or if not, from another appropriately authorised independent financial adviser. The whole of this Document should be read.

If you have sold or transferred all of your Existing Ordinary Shares on or before the Record Date, please send this Document as soon as possible to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for onward transmission to the purchaser or transferee. This Document should, however, not be forwarded to or transmitted into any jurisdiction outside of the UK if to do so would constitute a violation of the relevant law and/or regulations of such jurisdiction. Any failure to comply with such restriction may constitute a violation of the securities laws of any such jurisdiction. If you have sold or transferred only part of your holding of Ordinary Shares on or before the Record Date, you should retain this Document and consult the bank, stockbroker or other agent through whom the sale or transfer was made.

Any offer of the Retail Offer Shares will be conditional on the admission of such shares to trading on AIM (in reliance on the exception in paragraph 6(a) of Schedule 1 of the Public Offers and Admissions to Trading Regulations 2024 (SI 2024/105) ("**POATR**")). The New Shares will only be made available where the offer is conditional on the admission of the New Shares to trading on AIM (in reliance on the exception in paragraph 6(a) of Schedule 1 of the POATR) or otherwise in circumstances not resulting in an offer of relevant securities to the public in the UK within the meaning of Regulation 12 of the POATR. This Document does not constitute, and is not required to be, a prospectus for the purposes of the FCA's Prospectus Rules: Admission to Trading on a Regulated Market sourcebook. In addition, it does not constitute, and is not required to be, an admission document for the purposes of the AIM Rules. Accordingly, this Document has not been, and will not be, reviewed or approved by the FCA, the London Stock Exchange or any other authority or regulatory body.

The Company's Ordinary Shares are currently admitted to trading on AIM. Application will be made to the London Stock Exchange for the Placing Shares, the Subscription Shares and the Retail Offer Shares to be admitted to trading on AIM. The New Shares will not be admitted to trading on any other investment exchange. It is expected that the admission of (i) the Firm Placing Shares will become effective and that dealings will commence in those shares at 8.00 a.m. on 9 September 2026 ("**Initial Admission**"); and (ii) the Subscription Shares, the Conditional Placing Shares and the Retail Offer Shares, subject to the passing of the Fundraising Resolutions, will become effective and that dealings will commence at 8.00 a.m. on 25 September 2026 (the "**Subsequent Admission**" and together with Initial Admission, "**Admission**").

AIM is a market designed primarily for emerging or smaller companies to which a higher investment risk tends to be attached than to larger or more established companies. AIM securities are not admitted to the Official List. A prospective investor should be aware of the risks of investing in such companies and should make the decision to invest only after careful consideration and, if appropriate, consultation with an independent financial adviser. Neither the London Stock Exchange nor the FCA has examined or approved the contents of this Document. The AIM Rules are less demanding than those that apply to entities with securities admitted to the Official List. It is emphasised that no application is being made for admission of the Existing Ordinary Shares or the New Shares to the Official List.

FUTURA MEDICAL PLC

(*Incorporated and registered in England and Wales under the Companies Act 2006 with registered no. 04206001*)

PLACING AND SUBSCRIPTION OF 801,000,000 NEW SHARES AT 0.2 PENCE PER SHARE

RETAIL OFFER OF UP TO 75,000,000 NEW SHARES AT 0.2 PENCE PER SHARE

AND

NOTICE OF GENERAL MEETING

Nominated Adviser and Joint Broker	*Joint Broker and Sole Bookrunner*
Panmure Liberum Limited	**Turner Pope Investments (TPI) Ltd**

This Document (and the information contained herein) does not contain or constitute an offer of securities for sale, or solicitation of an offer to purchase securities, in the United States, Australia, Canada, Japan or the Republic of South Africa or any other jurisdiction where such an offer or solicitation would be unlawful. The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "**Securities Act**") or with any securities regulatory authority of any state or jurisdiction of the United States and may not be offered, sold, resold, or delivered, directly or indirectly, in or into the United States or to US persons unless the securities are registered under the Securities Act, or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, in each case in accordance with any applicable securities laws and regulations of any state or jurisdiction of the United States. The securities referred to herein were offered and sold only to non-US persons outside the United States in offshore transactions within the meaning of, and in accordance with, Regulation S under the Securities Act. There is no public offer of securities in the United States.

None of the New Shares, this Document or any other document connected with the Equity Fundraising have been or will be approved or disapproved by the US Securities and Exchange Commission or by the securities commissions of any state or other jurisdiction of the United States or any other regulatory authority, nor have any of the foregoing authorities or any securities commission passed comment upon or endorsed the merits of the offering of the New Shares or the accuracy or adequacy of this Document or any other document connected with the Equity Fundraising. Any representation to the contrary is a criminal offence in the United States.

The New Shares have not been and will not be registered under the securities laws and regulations of any jurisdiction, in particular, Australia, Canada, Japan or the Republic of South Africa, and may not be offered, sold, resold, or delivered, directly or indirectly, within Australia, Canada, Japan or the Republic of South Africa, or in any jurisdiction where it is unlawful to do so, except pursuant to an applicable exemption.

The distribution of this Document and the offer of the New Shares in certain jurisdictions may be restricted by law. Accordingly, neither this Document, nor any advertisement or any other offering material may be distributed or published in any jurisdiction except under circumstances that will result in compliance with any applicable laws and regulations. Persons outside of the UK into whose possession this Document comes should inform themselves about and observe any such restrictions.

You are recommended to read the whole of this Document but your attention is drawn, in particular, to the letter from the Non-Executive Chairman which is set out in Part I of this Document.

Notice of the General Meeting to be held at the offices of Panmure Liberum Limited at Ropemaker Place, Level 12, 25 Ropemaker Street, London, England, EC2Y 9LY at 10:00 a.m. on 23 September 2026, is set out at the end of this Document.

Shareholders are asked to cast their vote as follows: (1) casting your proxy vote online via the Investor Centre app or by accessing the web browser at https://uk.investorcentre.mpms.mufg.com/ and following the instructions; or (2) in the case of CREST members, by utilising the CREST electronic proxy appointment service in accordance with the procedures set out in the notice of the General Meeting; or (3) if you are an institutional investor you may also be able to appoint a proxy electronically via the Proxymity platform in accordance with the procedures set out in the notice of the General Meeting; or (4) requesting a hard copy form of proxy directly from the registrar, MUFG Corporate Markets at PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL. For further information, please refer to the notes to the Notice of General Meeting. If you choose to attend the General Meeting in person instead of appointing the chair of the meeting as proxy, you will still be able to vote in person at the General Meeting.

Any form of proxy for use in connection with the General Meeting should be completed by Shareholders and returned as soon as possible but, in any event, so as to be received by the Registrar, MUFG Corporate Markets at PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL no later than 10:00 a.m. on 21 September 2026 (or, in the case of an adjournment of the General Meeting, not later than 48 hours (excluding any part of a day that is not a working day) before the time fixed for the holding of the adjourned meeting). Alternatively, Shareholders who hold their shares in uncertificated form may use the CREST electronic proxy appointment service. In order for a proxy appointment made using the CREST service to be valid, the appropriate CREST message must be properly authenticated and contain the information required for such instructions as described in the CREST Manual. The message must be transmitted so as to be received by the Company's Registrar, MUFG Corporate Markets (ID RA10), by no later than 10:00 a.m. on 21 September 2026. Shareholders who hold Ordinary Shares in CREST may also appoint a proxy using CREST.

Completion and return of proxy votes will not preclude Shareholders from attending and voting in person at the General Meeting should they so wish.

Copies of this Document will be available free of charge to the public from the Company's website https://www.futuramedical.com/investor-centre/corporate-documentation/.

Panmure Liberum Limited ("**Panmure**") which is authorised and regulated in the United Kingdom by the Financial Conduct Authority and is a member of the London Stock Exchange, is acting exclusively for the Company as its Nominated Adviser and Joint Broker in connection with the Equity Fundraising and will not be offering advice and will not otherwise be responsible for providing customer protections to recipients of this Document or any other person in respect of the Equity Fundraising or any acquisition of New Shares. No representation or warranty, express or implied, is made by Panmure as to any of the contents of this Document for which the Directors and the Company are responsible (without limiting the statutory rights of any person to whom this Document is issued). Panmure has not authorised the contents of, or any part of, this Document, and no liability whatsoever is accepted by Panmure for the accuracy of information or opinions contained in this Document or for the omission of any material information from this Document. Panmure accordingly disclaims all and any liability, whether arising in tort, contract or otherwise, which it might otherwise be found to have in respect of this Document.

Turner Pope Investments (TPI) Ltd ("**Turner Pope**"), which is authorised and regulated by the FCA in the United Kingdom, is acting exclusively for the Company as its Joint Broker and Sole Bookrunner in connection with the Equity Fundraising and will not be offering advice and will not otherwise be responsible for providing customer protections to recipients of this Document or any other person in respect of the Equity Fundraising or any acquisition of New Shares. Turner Pope has also been appointed as the Retail Offer coordinator and is acting exclusively for the Company and no one else in connection with the Retail Offer and will not regard any other person (whether or not a recipient of this Document) as a client in relation to the Retail Offer and will not be responsible to anyone other than the Company for providing the protections afforded to its clients nor for giving advice in relation to the Retail Offer or any transaction or arrangement referred to in this Document. Apart from the responsibilities and liabilities, if any, that may be imposed on Turner Pope by FSMA or the regulatory regime established thereunder, or under the regulatory regime of any jurisdiction where the exclusion of liability under the relevant regulatory regime would be illegal, void or unenforceable, Turner Pope accepts no responsibility whatsoever for, and makes no representation or warranty, express or implied, as to any of the contents of this Document for which the Directors and the Company are responsible (without limiting the statutory rights of any person to whom this Document is issued). Turner Pope has not authorised the contents of, or any part of, this Document, and no liability whatsoever is accepted by Turner Pope for the accuracy of information or opinions contained in this Document or for the omission of any material information from this Document. Turner Pope accordingly disclaims all and any liability, whether arising in tort, contract or otherwise, which it might otherwise be found to have in respect of this Document.

No person has been authorised to give any information or to make any representation other than that contained in this Document in connection with the Equity Fundraising and, if given or made, such information or representation must not be relied upon as having been authorised by or on behalf of the Company, Panmure, Turner Pope or their respective directors, officers, partners, members, employees, advisers, affiliates or agents.

The contents of the Company's website or any website directly or indirectly linked to the Company's website do not form part of this Document.

Forward Looking Statements

This Document contains "forward-looking statements" which include all statements (other than statements of historical facts) including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include the words "targets", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "would", "could" or similar expressions or negatives thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. These forward-looking statements speak only as at the date of this Document. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based unless required to do so by applicable law or the AIM Rules.

CONTENTS

		Page
DIRECTORS, SECRETARY AND ADVISERS		5
EXPECTED TIMETABLE OF PRINCIPAL EVENTS		6
DEFINITIONS		7
PART I	LETTER FROM THE NON-EXECUTIVE CHAIRMAN OF FUTURA MEDICAL PLC	11
PART II	NOTICE OF GENERAL MEETING	22

DIRECTORS, SECRETARY AND ADVISERS

Directors:	Alexander Duggan *(Chief Executive Officer)* Angela Hildreth *(Finance Director and Chief Operating Officer)* Kenneth James *(Executive Director)* Andrew Unitt *(Non-Executive Chairman)* Roy Davis *(Non-Executive Director)*
Company Secretary:	Angela Hildreth
Registered Office:	Surrey Technology Centre 40 Occam Road Guildford Surrey GU2 7YG
Company Website:	https://www.futuramedical.com/
Nominated Adviser and Joint Broker:	**Panmure Liberum Limited** Ropemaker Place, Level 12 25 Ropemaker Street London EC2Y 9LY
Joint Broker and Sole Bookrunner:	**Turner Pope Investments (TPI) Ltd** 25 Bruton Street London W1J 6QH
Legal Advisers to the Company:	**Winston Taylor International LLP** 5 New Street Square London EC4A 3TW
Legal Advisers to Turner Pope and Panmure Liberum:	**DAC Beachcroft LLP** Woolgate 25 Basinghall Street London EC2V 5HA
Registrar:	**MUFG Corporate Markets** Central Square 29 Wellington Street Leeds LS1 4DL
Public Relations Adviser to the Company:	**Alma Strategic Communications Limited** 71 - 73 Carter Lane London EC4V 5EQ

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

Event	*Date*
Announcement of the Equity Fundraising	3 September 2026
Posting of this Document	4 September 2026
Latest time and date for receipt of bids for the Retail Offer on BookBuild	4:30 p.m. on 4 September 2026
Announcement of the results of the Retail Offer	7 September 2026
Initial Admission and commencement of dealings in the Firm Placing Shares	8.00 a.m. on 9 September 2026
CREST accounts to be credited with Firm Placing Shares	as soon as possible on 9 September 2026
Latest time and date for receipt of proxy votes to be valid at the General Meeting	10:00 a.m. on 21 September 2026
General Meeting	**10:00 a.m. on 23 September 2026**
Publication of the results of the General Meeting	23 September 2026
Despatch of definitive share certificates for Firm Placing Shares in certificated form	by 23 September 2026
Subsequent Admission and commencement of dealings in the Subscription Shares, the Conditional Placing Shares and the Retail Offer Shares	8.00 a.m. on 25 September 2026
CREST accounts to be credited with Subscription Shares, Conditional Placing Shares and Retail Offer Shares	as soon as possible on 25 September 2026
Despatch of definitive share certificates for Subscription Shares, Conditional Placing Shares and Retail Offer Shares in certificated form	by 9 October 2026

Notes

1. Each of the times and dates mentioned in this Document is subject to change by the Company (with the agreement of Panmure and Turner Pope), in which event details of the new times and dates will be notified to London Stock Exchange and the Company will make an appropriate announcement through a Regulatory Information Service.
2. References to times in this Document are to London time unless otherwise stated.
3. Certain of the events in the above timetable are conditional upon the approval of the Fundraising Resolutions at the General Meeting.
4. If you have questions on how to complete the Form of Proxy, please contact MUFG Corporate Markets via email at shareholderenquiries@cm.mpms.mufg.com or on 0371 664 0391 if calling from the United Kingdom, or +44(0)371 664 0391 if calling from outside the United Kingdom. Calls are charged at the standard geographical rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 – 17:30, Monday to Friday excluding public holidays in England and Wales.

DEFINITIONS

The following definitions apply throughout this Document, unless the context requires otherwise:

"Admission"	together, Initial Admission and Subsequent Admission
"AIM Rules for Companies"	the rules of AIM as set out in the publication entitled "AIM Rules for Companies" published by the London Stock Exchange from time to time
"AIM Rules for Nominated Advisers"	the rules of AIM as set out in the publication entitled "AIM Rules for Nominated Advisers" published by the London Stock Exchange from time to time
"AIM Rules"	the AIM Rules for Companies and/or the AIM Rules for Nominated Advisers (as the context may require)
"AIM"	the market of that name operated by the London Stock Exchange
"Announcement"	the RNS announcement issued by the Company dated 3 September 2026 in relation to the Equity Fundraising and the Formal Sale Process
"Board" or "Directors"	the board of directors of the Company, whose names are listed on page 4 of this Document
"BookBuild"	BB Technology Limited (company number 13508012) whose registered office is at Kinetic Business Centre, Theobald Street, Elstree, Hertfordshire, WD6 4PJ
"BookBuild Platform"	the online capital markets platform developed by BookBuild
"Bookrunner"	Turner Pope
"CA 2006"	the Companies Act 2006
"CCSS"	the CREST Courier and Sorting Service, established by Euroclear to facilitate, inter alia, the deposit and withdrawal of certificated securities
"certificated" or **"in certificated form"**	an Ordinary Share or other security recorded on a company's share register as being held in certificated form (that is not in CREST)
"Circular" or **"this Document"**	this circular of the Company incorporating (amongst other things) the Notice of General Meeting
"Company" or **"Futura"**	Futura Medical plc, a public limited company incorporated in England and Wales under registered number 04206001 and whose registered office address is at Surrey Technology Centre, 40 Occam Road, Guildford, Surrey, GU2 7YG
"Conditional Fundraising"	together, the Conditional Placing, the Subscription, the Retail Offer and the issue of the Warrants
"Conditional Placing"	the conditional placing by the Bookrunner (on behalf of the Company) of 719,367,225 Conditional Placing Shares to raise approximately £1.43 million in gross proceeds
"Conditional Placing Shares"	the 719,367,225 new Ordinary Shares to be issued for cash to Placees under the Conditional Placing conditional inter alia on the passing of the Fundraising Resolutions at the General Meeting
"CREST Manual"	the compendium of documents entitled "CREST Manual"

	published by Euroclear from time to time and comprising the CREST Reference Manual, the CREST Central Counterparty Service Manual, the CREST International Manual, the CREST Rules (including CREST Rule 8), the CREST CCSS Operating Manual and the CREST Glossary of Terms
"CREST member"	a person who has been admitted to CREST as a system member (as defined in the CREST Regulations)
"CREST Regulations"	the Uncertificated Securities Regulations 2001 (SI 2001/3755) (as amended from time to time)
"CREST sponsor"	a CREST participant admitted to CREST as a CREST sponsor
"CREST sponsored member"	a CREST member admitted to CREST as a sponsored member
"CREST"	the relevant system (as defined in the CREST Regulations) which enables title to units of relevant securities (as defined in the CREST Regulations) to be evidenced and transferred without a written instrument and in respect of which Euroclear is the Operator (as defined in the CREST Regulations)
"Enlarged Share Capital"	the entire issued share capital of the Company immediately following Subsequent Admission
"Euroclear"	Euroclear UK & International Limited, the operator of CREST
"Equity Fundraising"	together, the Placing, the Subscription and the Retail Offer
"Existing Ordinary Shares"	the Ordinary Shares in issue prior to the Equity Fundraising, all of which are admitted to trading on AIM
"FCA"	the United Kingdom Financial Conduct Authority
"Firm Placing"	the placing by the Bookrunner (on behalf of the Company) of 58,132,775 Firm Placing Shares to raise approximately £116,000 in gross proceeds
"Firm Placing Shares"	the 58,132,775 new Ordinary Shares to be issued for cash to Placees under the Firm Placing
"Form of Proxy"	the form of proxy for use by Shareholders in relation to the General Meeting
"Formal Sale Process"	the formal sale process announced by the Company in accordance with the provisions of the Takeover Code through which the Company intends to explore a range of strategic alternatives with the objective of maximising shareholder value (including the M&A Process)
"FSMA"	the Financial Services and Markets Act 2000 of the United Kingdom, as amended
"**Fundraising Resolutions**"	Resolutions 1 and 2 to be proposed at the General Meeting
"General Meeting"	the general meeting of the Shareholders of the Company to be held at the offices of Panmure at Ropemaker Place, Level 12, 25 Ropemaker Street, London, England, EC2Y 9LY at 10:00 a.m. on 23 September 2026, convened by the Notice of General Meeting which is set out at the end of this Document
"Group"	the Company, its subsidiaries and subsidiary undertakings from time to time
"Initial Admission"	the admission of the Firm Placing Shares to trading on AIM becoming effective by means of the issue by the London Stock Exchange of a dealing notice under Rule 6 of the AIM Rules

"Interim Results"	the Company's unaudited interim results for the six-months ended 30 June 2026
"Issue Price"	0.2 pence per New Share
"London Stock Exchange"	London Stock Exchange plc
"M&A Process"	the potential sale of one or more of the Company's assets and licensing or other commercial arrangements and the potential sale of the Company as a whole
"New Shares"	the 876,000,000 new Ordinary Shares to be issued pursuant to the Equity Fundraising
"Notice of General Meeting"	the notice of General Meeting which is set out at the end of this Document
"Official List"	the official list of the FCA
"Ordinary Shares"	ordinary shares of 0.2 pence each in the capital of the Company
"Panmure"	Panmure Liberum Limited a private limited company incorporated in England and Wales under company number 04915201 and having its registered office at Ropemaker Place, Level 12, 25 Ropemaker Street, London, England, EC2Y 9LY, the Company's nominated adviser and joint broker
"Placees"	eligible investors procured by the Bookrunner to subscribe for Placing Shares in the Placing
"Placing Agreement"	the conditional placing agreement dated 3 September 2026 relating to the Equity Fundraising made among the Company, Panmure and Turner Pope
"Placing Shares"	together, the Firm Placing Shares and the Conditional Placing Shares
"Placing"	together, the Firm Placing and the Conditional Placing
"**Placing Letters**"	the letters addressed to Turner Pope signed by each Placee in connection with the Placing
"POATR"	the Public Offers and Admissions to Trading Regulations 2024 (SI 2024/105), as amended
"Record Date"	6.00 p.m. on 21 September 2026
"Registrar" or **"MUFG Corporate Markets"**	MUFG Corporate Markets (UK) Limited a private limited company incorporated in England and Wales under company number 02605568 and having its registered office at Central Square, 29 Wellington Street, Leeds, United Kingdom, LS1 4DL, the Company's registrar
"Regulatory Information Service" or **"RIS"**	a regulatory information service operated by the London Stock Exchange, as defined in the AIM Rules for Companies
"Resolutions"	the resolutions to be proposed at the General Meeting as set out in the Notice of General Meeting
"**Retail Offer"**	the proposed conditional retail offer to existing retail Shareholders via the BookBuild Platform to raise up to £150,000 (before expenses) at the Issue Price
"Retail Offer Announcement"	the RNS announcement issued by the Company dated 3 September 2026 in relation to the Retail Offer
"Retail Offer Shares"	up to 75,000,000 new Ordinary Shares to be made available

	pursuant to the terms of the Retail Offer
"Shareholders" and each individually a **"Shareholder"**	the holders of Ordinary Shares
"Subsequent Admission"	the admission of the Conditional Placing Shares, the Subscription Shares and the Retail Offer Shares to trading on AIM becoming effective by means of the issue by the London Stock Exchange of a dealing notice under Rule 6 of the AIM Rules
"Subscribers"	those persons who have agreed to subscribe for the Subscription Shares pursuant to the Subscription, Alexander Duggan (*Chief Executive Officer*) (through his wholly owned company, Appia Healthcare Limited), Kenneth James (*Executive Director*), Andrew Unitt (*Non-Executive Chairman*) and Roy Davis (*Non-Executive Director*)
"Subscription"	the conditional subscription by the Subscribers for Subscription Shares at the Issue Price in accordance with the Subscription Letters to raise £47,000 before expenses
"Subscription Letters"	letters of application to subscribe for the Subscription Shares signed by the Subscribers
"Subscription Shares"	the 23,500,000 new Ordinary Shares to be issued pursuant to the Subscription
"Takeover Code"	The City Code on Takeovers and Mergers
"Turner Pope"	Turner Pope Investments (TPI) Ltd, a private limited company incorporated in England and Wales under company number 09506196 and having its registered office at Ground Floor, Kings House, 101-135 Kings Road, Brentwood, Essex, CM14 4DR, the Company's joint broker and sole bookrunner for the Placing
"UK" or **"United Kingdom"**	the United Kingdom of Great Britain and Northern Ireland
"uncertificated" or **"in uncertificated form"**	the description of a share or other security which is on the relevant register of the share or security concerned as being held in uncertificated form in CREST and title to which may be transferred by means of CREST
"US" or **"United States"**	the United States of America, its territories and possessions, any state of the United States and the District of Columbia
"Warrants"	the warrants to subscribe for up to 204,875,000 Ordinary Shares proposed to be issued, conditional inter alia on the passing of the Fundraising Resolutions at the General Meeting, to Turner Pope as further described in paragraph 4 of Part I of this Circular
"Warrant Shares"	the Ordinary Shares which are the subject of subscription rights (being rights to subscribe for Ordinary Shares for each Warrant held) conferred by the holding of the Warrants
"2025 Warrant Instrument"	the broker warrant instrument dated 2 December 2025 relating to warrants to subscribe for up to 34,375,000 Ordinary Shares
"2025 Warrants"	the warrants issued pursuant to the 2025 Warrant Instrument

All references in this Document to "**£**", "**pence**" or "**p**" are to the lawful currency of the United Kingdom.

All references to time in this Document are to London, UK time.

PART I

LETTER FROM THE NON-EXECUTIVE CHAIRMAN OF FUTURA MEDICAL PLC

(Incorporated and registered in England and Wales with registered no. 04206001)

Directors:	*Registered Office:*
Alexander Duggan *(Chief Executive Officer)*	Surrey Technology Centre
Angela Hildreth *(Finance Director and Chief Operating Officer)*	40 Occam Road
Kenneth James *(Executive Director)*	Guildford
Andrew Unitt *(Non-Executive Chairman)*	Surrey
Roy Davis *(Non-Executive Director)*	GU2 7YG

4 September 2026

Dear Shareholder,

Proposed Placing and Subscription of 801,000,000 New Shares to raise approximately £1.6 million
Proposed Retail Offer of up to 75,000,000 Retail Offer Shares
and
Notice of General Meeting

1. INTRODUCTION

On 3 September 2026, the Company announced that it proposed to undertake an Equity Fundraising to raise approximately £1.75 million in gross proceeds, subject to certain conditions. The Company has raised approximately £116,000 in gross proceeds pursuant to a firm placing of New Shares, has conditionally raised a further £1.43 million in gross proceeds pursuant to a conditional placing and a direct subscription of New Shares and proposes to raise up to a further £150,000 in gross proceeds pursuant to a retail offer, in each case at a price of 0.2 pence per share. In addition, as part of the compensation due to Turner Pope in consideration for their acting as Bookrunner in relation to the Placing, the Company intends to issue Turner Pope warrants to subscribe for up to 204,875,000 Ordinary Shares at an exercise price of 0.2 pence per share.

A total of 777,500,000 New Shares have been placed by the Bookrunner pursuant to the Placing with investors at the Issue Price, raising gross proceeds of approximately £1.56 million. In connection therewith, the Placees have each signed Placing Letters committing to subscribe, in aggregate, for the Placing Shares. The Subscribers have agreed to subscribe for an aggregate of 23,500,000 New Shares at the Issue Price, raising gross proceeds of approximately £47,000.

In addition to the Placing and the Subscription, the Board is pleased to offer existing retail Shareholders the opportunity to participate in the Equity Fundraising through the Retail Offer on the BookBuild Platform to raise a maximum of £150,000 (assuming full take up of the Retail Offer) through the issue of up to 75,000,000 Retail Offer Shares at the Issue Price. It is expected that the Retail Offer will close at 4:30 p.m. on 4 September 2026.

The Issue Price of 0.2 pence per New Share represents a discount of approximately 37.6 per cent. to the closing price of the Ordinary Shares on 2 September 2026, the last practicable date prior to the date of this Document.

The Company has in place sufficient shareholder authorities from its 2026 annual general meeting to undertake the Firm Placing, pursuant to which 58,132,775 new Ordinary Shares will be issued to Placees. However, the Company does not have sufficient shareholder authorities also to undertake the Conditional Fundraising. Therefore, the Conditional Fundraising is conditional inter alia on the passing of the Fundraising Resolutions at the General Meeting to be held at 10:00 a.m. on 23 September 2026. The Fundraising Resolutions are contained in the Notice of General Meeting set out in Part II of this

Document.

Applications will be made to the London Stock Exchange for the New Shares to be admitted to trading on AIM. It is expected that Initial Admission will occur at 8.00 a.m. on 9 September 2026 (or such other date as the Company and Turner Pope may agree, being no later than 8.00 a.m. on 30 September 2026) and that Subsequent Admission will occur at 8.00 a.m. on 25 September 2026 (or such other date as the Company, Turner Pope and Panmure may agree, being no later than 8.00 a.m. on 30 September 2026). The New Shares will represent approximately 60.1 per cent of the Enlarged Share Capital (assuming full take up of the Retail Offer) and, when issued, will rank *pari passu* with the Existing Ordinary Shares.

This letter explains why the Directors consider the Equity Fundraising and the related issue of Warrants to be in the best interests of the Company and its Shareholders as a whole.

This letter also contains the Directors' recommendation that Shareholders vote in favour of all of the Resolutions to be proposed at the General Meeting. The Directors, who in aggregate hold 1.02 per cent. of the Company's existing share capital, have signed irrevocable undertakings to vote in favour of all of the Resolutions at the General Meeting in respect of their own beneficial shareholdings.

The Resolutions are contained in the Notice of General Meeting contained in Part II of this Document.

On 1 September 2026, the Company announced its Interim Results. The Board strongly advise that this Document is read in conjunction with the Interim Results.

2. BACKGROUND TO AND REASONS FOR THE EQUITY FUNDRAISING

A. ***Overview***

The Company is the consumer healthcare group behind Eroxon®, specialising in the development and global commercialisation of innovative, clinically proven sexual health products, including Eroxon®, Eroxon® Intense and WSD4000.

Eroxon®

Eroxon® is the first clinically proven topical treatment for erectile dysfunction to achieve over-the-counter status in major international markets. Additionally, Eroxon® is the only FDA-cleared and drug-free, clinically proven treatment for erectile dysfunction, a key differentiator compared to competitors. It is estimated that erectile dysfunction affects hundreds of millions of men globally, with a significant proportion suffering from mild to moderate symptoms for which Eroxon® is specifically positioned. Within the US alone, it is estimated that 24.2% of US men have some form of erectile dysfunction[1].

Eroxon® Intense

Eroxon® Intense is a new formulation of Eroxon® which is designed to have a faster and stronger sensorial action. Marketing feedback on Eroxon® has shown that, whilst many men are satisfied with the current sensorial effect of the product, a faster and stronger sensation emphasising a stronger onset of action would be beneficial. Futura has recently completed all technical and regulatory work required to support commercial launch under the Company’s existing CE certification in accordance with the EU Medical Device Regulations (MDR 2017/745) together with UKCA (UK Conformity Assessment) certification. The Board currently expects to receive US FDA clearance in Q4 2026.

WSD4000

WSD4000 is the project name for the Company’s female sexual health portfolio, starting with the creation of a range of topical gels under its unique platform technology designed to treat impaired sexual response or function (sexual dysfunction) in women. Currently, no known regulatory approved topical treatments for sexual dysfunction in women are available over the counter in any major market, with the Company estimating that 60% of women have experienced at least one symptom of impaired sexual response and sexual function in the last 12 months, and that only 1 in 4 women seek professional help[2]. Therefore, WSD4000 has the potential to create effective, breakthrough treatments for the common symptoms associated with sexual dysfunction, such as impaired arousal, lubrication, orgasm and sexual

[1] *J Sex Med. 2024 Mar 28;21 (4) 296-303*

[2] *Market Research conducted by IPSOS showed 60% of women have experienced symptoms of sexual dysfunction over the last 12 months and 49% of women want to treat their symptoms. Current US female population between the ages of 22 and 75 is 113 million of which an estimated 68 million experience symptoms.*

satisfaction in various groups such as pre- and post-menopausal women.

2026 performance

As announced in August 2025, the Board commenced a comprehensive review of the Group's business, commercial strategy and funding requirements, the conclusions of which were reported in April 2026. While the sales offtake of Eroxon® progressed more slowly than originally anticipated, the review confirmed the strength of Futura's underlying intellectual property, product portfolio and development pipeline with regards to Eroxon®, Eroxon® Intense and WSD4000, as well as the significant long-term market opportunities available to the Group.

This view is further supported by Eroxon® distributor sales into the market (in-market sales), which provide a better view of how Eroxon® is actually performing than Futura's periodic sales to distributors. Over the four quarters to June 2026, the in-market sales across USA, Mexico, Europe and Middle East have begun to show greater stability as the product moves out of its early launch phase.

Throughout 2026, the Company has continued to make meaningful strategic progress:

1) In relation to Eroxon®

   - Grant of China patent on 30 December 2025
   - Grant of US continuation patent on 17 March 2026
   - Conclusion of commercial relationship with Haleon in June 2026 and receipt of the agreed settlement payment in August 2026
   - Appointment of Market Performance Group as the new US commercial partner for Eroxon® from 1 September 2026, following a two-month transition period from Haleon, providing a clear route to rebuilding momentum in one of the world's largest erectile dysfunction markets
   - Negotiations advanced in China in relation to domestic and cross-border opportunities. Additionally, new partners identified and discussions advanced in important new markets including Korea, Taiwan and Turkey
   - Finalised plans to consolidate production of Eroxon® (and Eroxon® Intense and WSD4000 at appropriate times) into one global strategic supplier

2) In relation to Eroxon® Intense

   - Home User Test (HUT) on 223 male subjects aged 18-59 completed; study showed high efficacy levels supporting commercial decision to launch
   - EU market launch clearance received, with FDA clearance expected in Q4 2026
   - Technical operations commenced to support production in Q1 2027

3) In relation to WSD4000

   - Positive results from an Early Feasibility Study (EFS), HUT and Placebo studies. The HUT demonstrated that WSD4000 markedly improved sexual function from using the product. 80% of women said the gel improved their overall sexual experience
   - Specialised agency analysis confirmed valuable consumer segments to target with positioning and products
   - Early-stage discussions commenced with potential commercial partners in USA, APAC, EMEA and LATAM with initial interest expressed

Collectively, the Board believes these milestones have reduced uncertainty surrounding the Company whilst increasing potential value, resulting in the creation of an attractive opportunity to test strategic interest in the business and its assets.

B. ***Reasons for the Equity Fundraising***

The Board recognises that additional funding would be required to realise fully the commercial potential of its portfolio. For example, the Company believes that conducting the pivotal study for WSD4000, which would support a full FDA-cleared claims platform for the product, would require an incremental investment of approximately £4 million. In the Board's view, continuing to raise capital as a standalone listed company could result in further shareholder dilution without guaranteeing the scale of resources required to maximise the value of the Group's assets. The Board therefore believes that now is the appropriate time to explore strategic alternatives, including, *inter alia*, additional or alternative partnering / licensing and distribution arrangements for Eroxon® alongside Eroxon® Intense, the sale of one or more of its assets or possible asset licensing arrangements or a sale of the Company as a whole, and that such a process is in the best interests of Shareholders and will allow it to assess a full range of opportunities to maximise shareholder value.

In order to explore whether a potential sale of the Company or any of its assets would provide a better outcome to stakeholders than the additional dilution arising from future funding requirements, the Company has launched a Formal Sale Process.

The Board believes the Equity Fundraising will provide sufficient financial stability for the Group to complete its strategic review and conduct the Formal Sale Process in an orderly manner, whilst continuing to progress the development of Eroxon® Intense and WSD4000. By extending the Company's cash runway into February 2027, the Equity Fundraising is intended to preserve the value of the Company's assets and allow the Board to evaluate strategic alternatives without undue financial pressure. The Board believes that there is long-term strategic and commercial value in the Company's assets and that this approach provides the best opportunity to realise that value for Shareholders.

3. CASH REQUIREMENT AND USE OF PROCEEDS

The gross proceeds of the Equity Fundraising will amount to approximately £1.75 million (assuming full take up of the Retail Offer).

The net proceeds of the Equity Fundraising will be used primarily to:

- strengthen the Company's working capital position, extending the Company's expected cash runway into February 2027;
- continue supporting the commercial development of Eroxon®, Eroxon® Intense and WSD4000, while maintaining the Company's core operations;
- fund the costs associated with the Formal Sale Process and broader strategic review; and
- provide the Board with the financial flexibility to conduct an orderly and comprehensive strategic process with the objective of maximising shareholder value.

4. DETAILS OF THE EQUITY FUNDRAISING

A. *Structure of the Placing*

The Directors have carefully considered the Company's financial situation and what financing options might be available to it and concluded that the Equity Fundraising is the only feasible financing option available to the Company and its Shareholders at this time.

The Placing Shares are not being offered to the public in any jurisdiction, and none of the Placing Shares are being offered or sold in any jurisdiction, where it would be unlawful to do so. This Document is not a prospectus and does not constitute or form part of any offer or invitation to purchase, acquire, subscribe for, sell, dispose of or issue, or any solicitation of any offer to sell, dispose of, purchase, acquire or subscribe for, any security, including any New Shares to be issued in connection with the Equity Fundraising.

B. Principal Terms of the Placing

Turner Pope, as agent for the Company, agreed in the Placing Agreement to use reasonable endeavours to procure Placees for the Placing Shares at the Issue Price. The Company will issue to Placees 58,132,775 Firm Placing Shares (raising gross proceeds of £116,000) and, subject inter alia to the passing of the Fundraising Resolutions at the General Meeting, 719,367,225 Conditional Placing Shares (raising gross proceeds of £1.43 million). The Placing is not underwritten. No commissions will be paid by Placees in respect of any Placing Shares.

Each Placee has signed a Placing Letter pursuant to which it has agreed to subscribe for Placing Shares at the Issue Price. In relation to Placees in the Conditional Placing, their commitment is conditional on, inter alia, the passing of the Fundraising Resolutions at the General Meeting.

C. The Subscription

The Subscribers have agreed to subscribe for 23,500,000 Subscription Shares at the Issue Price. The aggregate gross proceeds of the Subscription will amount to £47,000. The Subscription is not underwritten.

The following Directors have agreed to subscribe for Subscription Shares as detailed below:

Director	*Number of New Shares Subscribed for*	*Resulting holding post Subsequent Admission*	*Resulting holding as a % of the Enlarged Share Capital*(1)
Alexander Duggan (*Chief Executive Officer)*(2)	12,500,000	17,500,000	1.2%
Kenneth James (*Executive Director*)	2,500,000	3,299,501	0.2%
Andrew Unitt (*Non-Executive Chairman*)	6,000,000	6,068,717	0.4%
Roy Davis (*Non-Executive Director*)	2,500,000	2,540,295	0.2%

Notes:

(1) Assuming full take up of the Retail Offer, but excluding any exercise of the Warrants.

(2) Shares listed for Alexander Duggan will be subscribed for by Appia Healthcare Limited, which is wholly owned by Alexander Duggan.

Each Subscriber has signed a Subscription Letter pursuant to which it has agreed to subscribe for Subscription Shares at the Issue Price, conditional on, inter alia, the approval by Shareholders of the Fundraising Resolutions.

D. The Retail Offer

The Company has separately agreed to use the BookBuild Platform to undertake an intermediaries offer of Retail Offer Shares at the Issue Price, alongside the Placing, to existing retail Shareholders. The terms and conditions of the Retail Offer are set out in the Retail Offer Announcement. Turner Pope is acting as Retail Offer coordinator in relation to the Retail Offer.

The Retail Offer will, if taken up in full, result in the issue of 75,000,000 Retail Offer Shares, raising gross proceeds of up to £150,000, for the Company. The Retail Offer is not underwritten and is conditional, inter alia, upon the Fundraising Resolutions being passed at the General Meeting and Subsequent Admission occurring.

The Retail Offer will be open to eligible existing retail Shareholders in the United Kingdom at 7:05 a.m. on 3 September 2026 via the following website: https://www.bookbuild.live/deals/V1X0M7/authorised-intermediaries. The Retail Offer will close at 4:30 p.m. on 4 September 2026.

Existing retail Shareholders should make their own investigations into the merits of an investment in the Company. Nothing in this Document amounts to a recommendation to invest in the Company or amounts to investment, taxation or legal advice. It should be noted that a subscription for Retail Offer Shares and investment in the Company carries a number of risks. Existing retail Shareholders should take independent advice from a person experienced in advising on investment in securities such as the Retail Offer Shares if they are in any doubt.

E. ***Key investment risks***

The Retail Offer may involve a significant degree of risk including loss of capital, rarity of dividends, lack of liquidity and potential for dilution and should only be done as part of a diversified portfolio. The value of an investment and the income from it could go down as well as up. The return of your investment is not guaranteed, and you may get back less than you originally invested. Past performance is not an indicator of future performance. Suffering a loss on your investment is always a possibility. Capital is at risk.

The potential gains and losses that may arise from your investments will depend on your appetite for risk and how you manage your approach to risk. Investing all your money into one type of investment can be a high-risk strategy and concentrate risks to which you and that type of investment may be exposed. A managed approach to risk may be to diversify your investments you make across different companies' securities and different asset classes.

F. ***Proceeds of the Equity Fundraising***

The issue of the Firm Placing Shares is expected to raise aggregate gross proceeds of £116,000, the issue of the Conditional Placing Shares is expected to raise aggregate gross proceeds of £1.43 million and the issue of the Retail Offer Shares is expected to raise aggregate gross proceeds of £150,000 (assuming full take up of the Retail Offer). The Subscription is expected to raise aggregate gross proceeds of £47,000.

Therefore, the Equity Fundraising is expected to raise aggregate gross proceeds of £1.75 million, assuming full take up of the Retail Offer.

G. ***Application for Admission***

Applications will be made to the London Stock Exchange for the New Shares to be admitted to trading on AIM. Initial Admission is expected to take place, and dealings in the Firm Placing Shares are expected to commence, at 8.00 a.m. on 9 September 2026 (or such later time and/or date as may be agreed between the Company, Turner Pope and Panmure, being no later than 8.00 a.m. on 30 September 2026). Subject to, amongst other things, passing of the Fundraising Resolutions at the General Meeting, Subsequent Admission is expected to take place and dealings in the Conditional Placing Shares, the Subscription Shares and the Retail Offer Shares are expected to commence at 8.00 a.m. on 25 September 2026 (or such later time and/or date as may be agreed between the Company, Turner Pope and Panmure, being no later than 8.00 a.m. on 30 September 2026). No temporary documents of title will be issued.

H. ***Conditionality***

The Placing, Subscription and Retail Offer are conditional upon the Placing Agreement becoming unconditional and not having been terminated in accordance with its terms. The Placing Agreement is conditional upon, amongst other things, the following:

1) in relation to the Conditional Fundraising only, the passing without amendment of all the Fundraising Resolutions at the General Meeting;

2) the Company having complied with its obligations and having satisfied all conditions under the Placing Agreement, which fall to be performed on or satisfied prior to Initial Admission and/or Subsequent Admission, as appropriate; and

3) Initial Admission occurring by no later than 8.00 a.m. on 9 September 2026 or such later time and date (being not later than 8.00 a.m. on 30 September 2026) as the Company and Turner Pope may agree and Subsequent Admission occurring by no later than 8.00 a.m. on 25 September 2026 or such later time and date (being not later than 8.00 a.m. on 30 September 2026) as the Company and Turner Pope may agree.

If the conditions set out above are not satisfied or waived (where capable of waiver), the Placing, the Subscription and the Retail Offer will lapse, and the New Shares will not be allotted and issued and no monies will be received by the Company from investors in respect of the Equity Fundraising. If the Fundraising Resolutions are not approved at the General Meeting, the Company will only receive the gross proceeds of the Firm Placing, being £116,000 and not the proceeds of the Conditional Placing, the Subscription and/or the Retail Offer.

I. ***Effect of the Equity Fundraising***

The New Shares will, following Admission, rank *pari passu* in all respects with the Existing Ordinary Shares and will carry the right to receive all dividends and distributions declared, made or paid on or in respect of the Ordinary Shares after the relevant Admission.

J. ***Warrants***

In connection with the Placing and subject to the passing of the Fundraising Resolutions and Subsequent Admission, the Company has agreed with Turner Pope that it will: (i) cancel the 2025 Warrant Instrument and the 2025 Warrants; and (ii) issue the Warrants to Turner Pope (or to such other persons as directed by Turner Pope).

The 2025 Warrant Instrument and the 2025 Warrants are being cancelled because the Company has agreed with Turner Pope that it will re-price the 2025 Warrants such that they are subject to the same exercise price and are on the same terms as the Warrants. As the terms of the 2025 Warrants are governed by the 2025 Warrant Instrument, effecting such re-pricing requires the cancellation of the existing 2025 Warrant Instrument and the 2025 Warrants, and the issue of new warrants (the Warrants), which will be on the revised terms set out in this Document.

The Warrants, which are freely transferable by the initial Warrant holder but not by any subsequent Warrant holder, will entitle the Warrant holder(s) to subscribe for (in aggregate) up to 204,875,000 Ordinary Shares at a subscription price of 0.2 pence (0.2p) per Ordinary Share (the "**Subscription Price**"), being equal to the Issue Price. The Subscription Price will be payable by the Warrant holder in cash on exercise of the Warrants.

The Warrant holder may exercise the Warrants (in whole or in part, subject to a minimum exercise amount) at any time and from time to time, from and including the date of Subsequent Admission up to (and including) the fifth anniversary of Subsequent Admission (the "**Subscription Period**"). Each Warrant will be cancelled once the subscription rights attaching to it have been exercised and the Warrant Shares allotted pursuant to such exercise.

The Subscription Price payable by the Warrant holder upon exercise of the Warrants will be adjusted on the occurrence of certain adjustment events, including (without limitation) any allotment or issue of fully paid shares by way of capitalisation of profits or reserves to Shareholders, or any sub-division or consolidation of Ordinary Shares, in each case on a date prior to the end of the Subscription Period, but the Exercise Price can never be less than the nominal value of an Ordinary Share.

K. ***Dilution***

Upon Subsequent Admission, Shareholders who do not participate in the Equity Fundraising will experience a dilution to their interests of approximately 60.1 per cent. (assuming the Fundraising Resolutions are passed, full take up of the Retail Offer and the Equity Fundraising completes before any exercise of the Warrants). If the Warrants are exercised in full, Shareholders who do not participate in the Equity Fundraising would experience a dilution to their interests of approximately 65 per cent. (assuming full take up of the Retail Offer).

5. THE PLACING AGREEMENT

Pursuant to the terms and subject to the conditions of the Placing Agreement, the Bookrunner, as agent for the Company, agreed to use reasonable endeavours to procure Placees to subscribe for the Placing Shares at the Issue Price. The Placing Agreement is conditional upon, amongst other things, the conditions set out in paragraph 4(H) above.

The Company has agreed under the Placing Agreement to pay to Turner Pope: (i) commissions based on the number of the New Shares allotted, multiplied by the Issue Price; (ii) a corporate finance fee; and (iii) certain other fees. In addition and as remuneration for its services as

Bookrunner, the Company will, subject to the passing of the Fundraising Resolutions and Subsequent Admission, issue the Warrants to Turner Pope. Panmure will also receive a corporate finance fee from the Company for its services as nominated adviser in connection with the Equity Fundraising.

The Placing Agreement contains customary warranties given by the Company in favour of Turner Pope and Panmure in relation to, amongst other things, the accuracy of the information in this Document and other matters relating to the Group and its business. In addition, the Company has agreed to indemnify Turner Pope and Panmure (and certain of their respective affiliates) in relation to certain liabilities which they may incur in respect of the Equity Fundraising.

Turner Pope has the right to terminate its obligations under the Placing Agreement in certain circumstances prior to Admission. In particular, in the event of breach of the warranties or if the Placing Agreement does not become unconditional, Turner Pope may terminate its obligations in connection with the Equity Fundraising and the New Shares will not be issued.

6. GENERAL MEETING

The Company has in place sufficient shareholder authorities granted at its 2026 annual general meeting to allot new Ordinary Shares pursuant to the Firm Placing. However, the Directors do not currently have sufficient authority also to allot the Conditional Placing Shares, the Subscription Shares, the Retail Offer Shares or issue the Warrants and, accordingly, the Board will be seeking the approval of Shareholders of the Fundraising Resolutions at the General Meeting in order to carry out the Conditional Fundraising. In addition, the Directors are seeking to renew the Company's authorities sought at the Company's last annual general meeting relating to the allotment of shares and disapplication of pre-emption rights, based on the Enlarged Share Capital.

The Directors, who in aggregate hold 1.02 per cent. of the Company's existing share capital, have signed irrevocable undertakings to vote in favour of all of the Resolutions at the General Meeting in respect of their own beneficial shareholdings.

The General Meeting of the Company, notice of which is set out at the end of this Document, is to be held at the offices of Panmure at Ropemaker Place, Level 12, 25 Ropemaker Street, London, England, EC2Y 9LY at 10:00 a.m. on 23 September 2026. The General Meeting is being held for the purpose of considering and, if thought fit, passing the Resolutions.

A summary and explanation of the Resolutions is set out below. Please note that this is not the full text of the Resolutions and you should read this section in conjunction with the Resolutions contained in the Notice of General Meeting in Part II of this Document. The Resolutions comprise:

Resolution 1 – an ordinary resolution to authorise the Directors to allot relevant securities for the purposes of section 551 of the CA 2006 up to an aggregate nominal amount of £2,045,485 pursuant to the Conditional Fundraising (including the issuance of the Warrants).

Resolution 2 – a special resolution to authorise the Directors to allot equity securities for cash, pursuant to the authority conferred on them by Resolution 1, and to dis-apply statutory pre-emption rights in respect of the allotment of such shares, as if section 561 of the CA 2006 did not apply to such allotment, with such authority being limited to the allotment of the Conditional Placing Shares, the Subscription Shares, the Retail Offer Shares and the issue of the Warrants. This Resolution is conditional upon the passing of Resolution 1.

The authorities and the powers described in Resolutions 1 and 2 will (unless previously revoked or varied by the Company in general meeting) expire on the date which is three months from the passing of such Resolutions. The authority and the power described in Resolutions 1 and 2 are in addition to any like authority or power previously conferred on the Directors.

Resolution 3 – an ordinary resolution to authorise the Directors to allot relevant securities for the purposes of section 551 of the CA 2006 up to an aggregate nominal amount of £1,943,104 (representing up to 971,551,837 Ordinary Shares) for the general purposes of the Company. This Resolution is conditional upon the passing of Resolutions 1 and 2.

Paragraph (a) of Resolution 3 would allow the Directors to allot new shares and grant rights to subscribe for or convert any securities into shares up to an aggregate nominal value of £971,552. This represents up to 485,775,918 Ordinary Shares, which is equivalent to approximately one-third of the Company's Enlarged Share Capital.

Paragraph (b) of Resolution 3 proposes that the Directors be authorised to allot shares in connection with a rights issue in favour of holders of equity securities, including Shareholders. The allotments would be made in accordance with the rights of those securities (or as the Directors may otherwise consider necessary) up to an aggregate nominal amount of £1,943,104 representing up to 971,551,837 Ordinary Shares, which is equivalent to approximately two-thirds of the Company's Enlarged Share Capital.

The authority sought under Resolution 3 will, if granted, lapse at the end of the next annual general meeting of the Company or, if earlier, 15 months from the date on which Resolution 3 is passed.

Resolutions 4 and 5 – special resolutions to authorise the Directors to allot equity securities for cash, pursuant to the authority conferred on them by Resolution 3, and to disapply statutory pre-emption rights in respect of the allotment of such shares, as if section 561 of the CA 2006 did not apply to such allotment, for the general purposes of the Company. Resolution 4 is conditional upon the passing of Resolutions 1 to 3 (inclusive) and Resolution 5 is conditional upon the passing of Resolutions 1 to 4 (inclusive).

If Resolution 4 is passed, under limb (b), it would allow the Directors to allot new shares for cash without first offering them to Shareholders in proportion to their existing holdings, whether or not the allotment is connected with an acquisition or specified capital investment up to an aggregate nominal amount of £291,466. This maximum amount represents up to 145,732,776 Ordinary Shares, which is equivalent to approximately 10 per cent of the Enlarged Share Capital (assuming full take up of the Retail Offer).

Further, under limb (c), Resolution 4 would, if passed, allow the Directors to allot new shares up to an aggregate nominal amount of £58,293, which represents approximately 2 per cent of the Enlarged Share Capital (assuming full take up of the Retail Offer), to be used only for the purposes of making a follow-on offer to retail investors or existing investors not allocated shares in the offer made under limb (b) of Resolution 4.

If Resolution 5 is passed, it would, under limb (a), allow the Directors to allot new shares for cash without first offering them to Shareholders in proportion to their existing holdings if the allotment is connected with an acquisition or specified capital investment (as described above), up to an aggregate nominal amount of £291,466. This maximum amount represents up to 145,732,776 Ordinary Shares, which is equivalent to approximately 10 per cent of the Enlarged Share Capital (assuming full take up of the Retail Offer).

The Directors intend to use the power given to them under Resolution 5 only in connection with an acquisition or specified capital investment which is announced contemporaneously with the relevant issue of Ordinary Shares, or which has taken place in the preceding six-month period and is disclosed in the announcement of the relevant issue of Ordinary Shares.

Resolutions 4 and 5 are in line with the Pre-emption Group's Statement of Principles for the Disapplication of Pre-emption Rights (the "**Statement of Principles**"). The Statement of Principles describes a specified capital investment as being one or more specific capital investment related uses for the proceeds of an issuance of equity securities, in respect of which sufficient information regarding the effect of the transaction on the listed company, the assets the subject of the transaction and (where appropriate) the profits attributable to them is made available to shareholders to enable them to reach an assessment of the potential return.

Further, under limb (b), Resolution 5 would, if passed, allow the Directors to allot new shares up to an aggregate nominal amount of £58,293, which represents approximately 2 per cent of the Enlarged Share Capital (assuming full take up of the Retail Offer), to be used only for the purposes of making a follow-on offer to retail investors or existing investors not allocated shares in the offer made under limb (a) of Resolution 5.

The authorities sought under Resolutions 4 and 5 will, if granted, lapse at the end of the

Company's next annual general meeting or, if earlier, 15 months from the date of the passing of Resolutions 4 and 5.

The Directors have no present intention to exercise the authorities sought under Resolutions 3, 4 and 5.

7. ACTION TO BE TAKEN IN RESPECT OF THE GENERAL MEETING

Shareholders should complete and submit a Form of Proxy (whether online or by requesting a hard copy from MUFG Corporate Markets) in accordance with the instructions printed on it. Shareholders will not receive a hard copy form of proxy for the General Meeting in the post. Instead, Shareholders will be able to vote electronically via the Investor Centre app or by accessing the web browser at https://uk.investorcentre.mpms.mufg.com/, or via the Proxymity platform (in the case of institutional investors) and following the instructions. The Form of Proxy (if completed in hard copy) must be received by the Company's registrar, MUFG Corporate Markets at PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL, by no later than 10:00 a.m. on 21 September 2026.

CREST members can also appoint proxies by using the CREST electronic appointment service and transmitting a CREST Proxy Instruction in accordance with the procedures set out in the CREST Manual so that it is received by MUFG Corporate Markets (under CREST participant RA10) by no later than 10:00 a.m. on 21 September 2026. The time of receipt will be taken to be the time from which MUFG Corporate Markets is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST.

Shareholders are strongly encouraged to complete and return the online proxy form appointing the Chair of the meeting as their proxy even if they are intending to attend the meeting.

Shareholders who hold their Ordinary Shares through a nominee should instruct their nominees to submit a Form of Proxy (whether online or by requesting a hard copy from MUFG Corporate Markets) on their behalf.

Shareholders are reminded that if the Fundraising Resolutions are not passed, the Company will not have sufficient authority to undertake the Conditional Fundraising.

8. IMPORTANCE OF VOTE

In the event that the Fundraising Resolutions are not passed, the Conditional Placing, the Subscription and the Retail Offer would not proceed and, as such, the anticipated net proceeds of the Equity Fundraising would not become available to the Company. There is no certainty that other funding would be available on suitable terms or at all. Accordingly, in light of the Group's limited cash runway, which as previously announced currently extends into October 2026, it is unlikely that the Company would be able to proceed with the planned M&A Process or Formal Sale Process to a conclusion. Should the Board conclude at any point that the M&A Process or Formal Sale Process is unlikely to result in a value-maximising transaction, the Directors would need to take appropriate action at that point, including consideration of an orderly wind-down, solvent or insolvent, or an accelerated insolvent sale in order to preserve value and ensure that the Group continues to meet its obligations as they fall due.

9. IRREVOCABLE UNDERTAKINGS

The Company has received irrevocable undertakings to vote in favour of the Resolutions from Directors who hold, in aggregate 5,908,513 Ordinary Shares, representing 1.02 per cent. of the Existing Ordinary Shares.

10. RECOMMENDATION

The Conditional Fundraising is conditional, inter alia, upon the passing of all of the Fundraising Resolutions at the General Meeting. If the Fundraising Resolutions are not passed at the General Meeting, the Conditional Fundraising will not take place and the proceeds of the Conditional Fundraising will not be received by the Company.

The Directors believe that if the Conditional Fundraising does not proceed, it is likely that the Company would be unable to complete the Formal Sale Process, thereby preventing any realisation of value from a sale of its business or assets, and would have to commence insolvency proceedings.

Accordingly, the Directors consider that the Conditional Fundraising and the passing of the Fundraising Resolutions are in the best interests of the Company and its Shareholders as a whole and the Directors unanimously recommend that Shareholders vote in favour of all of the Fundraising Resolutions.

In addition, the Directors believe that the passing of Resolutions 3, 4 and 5 at the General Meeting are in the best interests of the Company and its Shareholders as a whole. Accordingly, the Directors unanimously recommend that Shareholders also vote in favour of Resolutions 3, 4 and 5 at the General Meeting.

Those Directors who hold Ordinary Shares have undertaken to vote in favour of all of the Resolutions at the General Meeting, by virtue of having signed irrevocable undertakings, in respect of their beneficial holdings of an aggregate of 5,908,513 Ordinary Shares, representing approximately 1.02 per cent. of the Existing Ordinary Shares.

Yours faithfully,

Andrew Unitt

Non-Executive Chairman

PART II

NOTICE OF GENERAL MEETING

FUTURA MEDICAL PLC

(Incorporated and registered in England and Wales under number 04206001)

(the "Company")

NOTICE IS HEREBY GIVEN that a general meeting of the Company will be held on 23 September 2026 at 10:00 a.m. (London time) at the offices of Panmure Liberum Limited at Ropemaker Place, Level 12, 25 Ropemaker Street, London, England, EC2Y 9LY for the purpose of considering and, if thought fit, passing the following resolutions, of which resolutions 1 and 3 will be proposed as ordinary resolutions and resolutions 2, 4 and 5 will be proposed as special resolutions.

In this Notice, words and defined terms shall have the same meaning as words and defined terms in the Circular to which this Notice is attached.

RESOLUTIONS

Ordinary Resolution

1. **THAT** the Directors be and are hereby generally and unconditionally authorised pursuant to section 551 of the Companies Act 2006 (the "**CA 2006**") (in addition to all existing authorities conferred upon the Directors pursuant to section 551 of the CA 2006 which shall continue in full force and effect) to exercise all the powers of the Company to allot shares in the capital of the Company and to grant rights to subscribe for or convert any security into such shares (all of which transactions are hereafter referred to as an allotment of "**Relevant Securities**") up to an aggregate nominal amount of £2,045,485, in connection with the Conditional Fundraising (including the issuance of the Warrants), provided that such authority shall expire (unless previously renewed, varied or revoked by the Company in general meeting) on the date which is three months after the date of passing of this resolution, but the Directors may before such expiry, revocation or variation make an offer or agreement which would or might require Relevant Securities to be allotted after such expiry, revocation or variation and the Directors may allot Relevant Securities in pursuance of such offer or agreement as if the authority hereby conferred had not expired or been revoked or varied.

Special Resolution

2. **THAT**, subject to the passing of Resolution 1 above (and in addition to all existing unexercised powers of the Directors under sections 570 and 571 of the CA 2006, which shall continue in full force and effect), the Directors be and are hereby empowered pursuant to section 570 of the CA 2006 to allot equity securities (within the meaning of section 560 of the CA 2006) for cash pursuant to the authority granted by Resolution 1 above as if section 561 of the CA 2006 did not apply to any such allotment, provided that such power shall:
   a) be limited to the allotment of equity securities in connection with the Conditional Fundraising (including the issuance of the Warrants); and
   b) expire (unless previously renewed, varied or revoked by the Company in general meeting) on the date which is three months after the date of passing of this resolution.

Ordinary Resolution

3. **THAT**, subject to the passing of Resolutions 1 and 2 above, the Directors be and are generally and unconditionally authorised for the purposes of section 551 of the CA 2006 to exercise all the powers of the Company to allot shares in the Company and to grant rights to subscribe for or to convert any security into shares in the Company:

   (a) up to an aggregate nominal amount of £971,552 (such amount to be reduced by any allotments or grants made under paragraph (b) below in excess of such amount); and

(b) comprising equity securities (as defined in section 560(1) of the CA 2006) up to an aggregate nominal amount of £1,943,104 (such amount to be reduced by any allotments or grants made under paragraph (a) above) in connection with an offer to:

(i) ordinary shareholders in proportion (as nearly as may be practicable) to the respective number of ordinary shares held by them on the record date for such allotment; and

(ii) holders of other equity securities if this is required by the rights of those securities or, subject to such rights, as the directors otherwise consider necessary, save that the directors may impose any limits or restrictions and make any arrangements which they consider necessary or expedient to deal with any fractional entitlements, record dates, legal, regulatory or practical problems in, or laws of, any territory or the requirements of any regulatory body or stock exchange or any other matter, provided that:

(A) (unless previously revoked, varied or renewed by the Company) this authority will expire at the end of the next annual general meeting of the Company or, if earlier, 15 months from the date of the passing of this resolution, save that the Directors may, before this authority expires, make offers or agreements which would or might require shares in the Company to be allotted, or rights to subscribe for or convert securities into shares to be granted, after its expiry and the Directors may allot shares or grant rights to subscribe for or convert securities into shares pursuant to such offers or agreements as if this authority had not expired; and

(B) this authority replaces all subsisting authorities previously granted to the Directors for the purposes of section 551 (save for that conferred by Resolution 1 above, which authority shall remain in full force and effect) which, to the extent unused at the date of this resolution, are revoked with immediate effect*,* without prejudice to any allotment of shares or grant of rights already made, offered or agreed to be made under such authorities.

Special Resolutions

4. **THAT**, subject to the passing of Resolutions 1 to 3 (inclusive) above, the Directors be authorised to allot equity securities (as defined in the CA 2006) for cash under the authority given by Resolution 3 as if section 561 of the CA 2006 did not apply to any such allotment or sale, such authority to be limited:

(a) to the allotment of equity securities for cash in connection with an offer by way of rights, an open offer or another pre-emptive offer to:

(i) ordinary shareholders in proportion (as nearly as may be practicable) to the respective number of ordinary shares held by them on the record date for such allotment; and

(ii) holders of other equity securities, if required by the rights of those securities or, subject to such rights, as the Directors otherwise consider necessary, subject, in both cases, to the power of the Directors to impose any limits or restrictions and make any arrangements which they consider necessary or appropriate to deal with any fractional entitlements, record dates, legal, regulatory or practical problems in, or laws of, any territory or the requirements of any regulatory body or stock exchange or any other matter, and

(b) to the allotment of equity securities (otherwise than under paragraph 4(a) above) up to a nominal amount of £291,466; and

(c) to the allotment of equity securities (otherwise than under paragraph 4(a) or paragraph 4(b) above) up to a nominal amount equal to 20 per cent. of any allotment of equity securities from time to time under paragraph 4(b) above, such authority to be used only for the purposes of making a follow-on offer which the Directors determine to be of a kind contemplated by paragraph 3 of Section 2B of the Pre-emption Group's Statement of Principles for the Disapplication of Pre-emption Rights most recently published prior to the date of this notice (the "**Statement of Principles**"), such authority to expire at the end of the next annual general meeting of the Company (or, if earlier, at the close of business on the date which is fifteen months after the date of the passing of this resolution) but, in each case, prior to its expiry the Company may make offers, and enter into agreements, which would, or might, require equity securities to be allotted after the authority expires and the Directors may allot equity securities under any such offer or agreement as if the authority had not expired.

5. **THAT,** subject to the passing of Resolutions 1 to 4 (inclusive) above, the Directors be authorised in addition to any authority granted under Resolution 4 to allot equity securities (as defined in the CA 2006) for cash under the authority given by Resolution 3 as if section 561 of the CA 2006 did not apply to any such allotment or sale, such authority to be:

(a) limited to the allotment of equity securities up to a nominal amount of £291,466 such authority to be used only for the purposes of financing (or refinancing, if the authority is to be used within 12 months after the original transaction) a transaction which the Directors determine to be either an acquisition or a specified capital investment of a kind contemplated by the Statement of Principles; and

(b) limited to the allotment of equity securities (otherwise than under paragraph (a) above) up to a nominal amount equal to 20 per cent. of any allotment of equity securities from time to time under paragraph (a) above, such authority to be used only for the purposes of making a follow-on offer which the Directors of the Company determine to be of a kind contemplated by paragraph 3 of Section 2B of the Statement of Principles,

such authority to expire at the end of the next annual general meeting of the Company (or, if earlier, at the close of business on the date which is fifteen months after the date of the passing of this resolution) but, in each case, prior to its expiry the Company may make offers, and enter into agreements, which would, or might, require equity securities to be allotted after the authority expires and the Directors may allot equity securities under any such offer or agreement as if the authority had not expired.

4 September 2026

By order of the Board

Angela Hildreth
Company Secretary

Futura Medical plc
Surrey Technology Centre
40 Occam Road, Guildford, Surrey, GU2 7YG
Registered in England and Wales No. 04206001

NOTICE OF GENERAL MEETING NOTES

The following notes explain your general rights as a shareholder and your rights to attend and vote at the General Meeting or to appoint someone else to vote at the General Meeting on your behalf.

1. To be entitled to attend and vote at the General Meeting (and for the purpose of the determination by the Company of the number of votes they may cast). Shareholders must be registered in the register of members of the Company at close of trading on 21 September 2026. Changes to the register of members after the relevant deadline shall be disregarded in determining the rights of any person to attend and vote at the General Meeting.

2. Shareholders are entitled to appoint another person as a proxy to exercise all or part of their rights to attend and to speak and vote on their behalf at the General Meeting. A shareholder may appoint more than one proxy in relation to the General Meeting provided that each proxy is appointed to exercise the rights attached to a different Ordinary Share or Ordinary Shares held by that shareholder. A proxy need not be a shareholder of the Company.

3. In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company's register of members in respect of the joint holding (the first named being the most senior).

4. A vote withheld is not a vote in law, which means that the vote will not be counted in the calculation of votes for or against the resolution. If no voting indication is given, your proxy will vote or abstain from voting at his or her discretion. Your proxy will vote (or abstain from voting) as he or she thinks fit in relation to any other matter which is put before the General Meeting.

5. All resolutions at the General Meeting will be decided by poll. The Directors believe a poll is more representative of Shareholders' voting intentions because shareholders' votes are counted according to the number of shares held and all votes tendered are taken into account.

6. Shareholders are asked to cast their vote as follows:

   (a) via the Investor Centre app or by accessing the web browser at https://uk.investorcentre.mpms.mufg.com/ and following the instructions (see below); if you need help with voting online please contact our registrar, MUFG Corporate Markets, on 0371 664 0391 if calling from the UK, or +44 (0)371 664 0391 if calling from outside of the UK, or email MUFG Corporate Markets at shareholderenquiries@cm.mpms.mufg.com;

   (b) in the case of CREST members, by utilising the CREST electronic proxy appointment service in accordance with the procedures set out below. In order for a proxy appointment to be valid a form of proxy must be completed;

   (c) by requesting a hard copy form of proxy directly from the registrar, MUFG Corporate Markets, via email at shareholderenquiries@cm.mpms.mufg.com or on Tel: 0371 664 0391. Calls are charged at the standard geographical rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales;

   (d) if you are an institutional investor you may also be able to appoint a proxy electronically via the Proxymity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io; and

   (e) in any case in order to be valid the form of proxy must be received by MUFG Corporate Markets at PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL by no later than 10:00 a.m. on 21 September 2026.

7. If you return more than one proxy appointment, either by paper or electronic communication, the appointment received last by the registrar before the latest time for the receipt of proxies will take precedence. You are advised to read the terms and conditions of use carefully. Electronic communication facilities are open to all shareholders and those who use them will not be disadvantaged.

8. Investor Centre is a free app for smartphone and tablet provided by MUFG Corporate Markets (the company's registrar). It allows you to securely manage and monitor your shareholdings in real time, take part in online voting, keep your details up to date, access a range of information including payment history and much more. The app is available to download on both the Apple App Store and Google Play, or by scanning the relevant QR code below. Alternatively, you may access the Investor Centre via a web browser at https://uk.investorcentre.mpms.mufg.com/.

Download on the App Store   GET IT ON Google Play

9. CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so for the General Meeting (and any adjournment of the General Meeting) by using the procedures described in the CREST Manual (available from www.euroclear.com). CREST personal members or other CREST sponsored members, and those CREST members who have appointed a service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.

10. In order for a proxy appointment or instruction made by means of CREST to be valid, the appropriate CREST message (a "CREST Proxy Instruction") must be properly authenticated in accordance with Euroclear's specifications and must contain

the information required for such instructions, as described in the CREST Manual. The message must be transmitted so as to be received by the issuer's agent (ID RA10) by no later than 10:00 a.m. on 21 September 2026. For this purpose, the time of receipt will be taken to mean the time (as determined by the timestamp applied to the message by the CREST application host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time, any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means.

11. CREST members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear does not make available special procedures in CREST for any particular message. Normal system timings and limitations will, therefore, apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member, or sponsored member, or has appointed (a) voting service provider(s) to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting system providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings. The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the CREST Regulations.

12. If you are an institutional investor you may also be able to appoint a proxy electronically via the Proxymity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io. Your proxy must be lodged by no later than 10:00 a.m. on 21 September 2026 in order to be considered valid or, if the General Meeting is adjourned, by the time which is 48 hours before the time of the adjourned meeting. Before you can appoint a proxy via this process you will need to have agreed to Proxymity's associated terms and conditions. It is important that you read these carefully as you will be bound by them and they will govern the electronic appointment of your proxy. An electronic proxy appointment via the Proxymity platform may be revoked completely by sending an authenticated message via the platform instructing the removal of your proxy vote.

    Unless otherwise indicated on the Form of Proxy, CREST, Proxymity or any other electronic voting instruction, the proxy will vote as they think fit or, at their discretion withhold from voting.

13. Any corporation which is a shareholder can appoint one or more corporate representatives who may exercise on its behalf all of its powers as a shareholder provided that no more than one corporate representative exercises powers in relation to the same shares.

14. As at 3 September 2026 (being the latest practicable business day prior to the publication of this Notice), the Company's ordinary issued and conditionally issued share capital consists of 581,327,755 Ordinary Shares, carrying one vote each. The Company holds no Ordinary Shares in treasury. On this basis, the total voting rights in the Company as at 3 September 2026 are 581,327,755.

15. Under Section 527 of the CA 2006, shareholders meeting the threshold requirements set out in that section have the right to require the Company to publish on a website a statement setting out any matter relating to:

    (a) the audit of the Company's financial statements (including the auditor's report and the conduct of the audit) that are to be laid before the General Meeting; or

    (b) any circumstances connected with an auditor of the Company ceasing to hold office since the previous meeting at which annual financial statements and reports were laid in accordance with Section 437 of the CA 2006 (in each case) that the shareholders propose to raise at the relevant meeting.

    The Company may not require the shareholders requesting any such website publication to pay its expenses in complying with Sections 527 or 528 of the CA 2006. Where the Company is required to place a statement on a website under Section 527 of the CA 2006, it must forward the statement to the Company's auditor not later than the time when it makes the statement available on the website. The business which may be dealt with at the General Meeting for the relevant financial year includes any statement that the Company has been required under Section 527 of the CA 2006 to publish on a website.

16. Any shareholder attending the General Meeting has the right to ask questions. The Company must cause to be answered any such question relating to the business being dealt with at the General Meeting but no such answer need be given if:

    (a) to do so would interfere unduly with the preparation for the General Meeting or involve the disclosure of confidential information;

    (b) the answer has already been given on a website in the form of an answer to a question; or

    (c) it is undesirable in the interests of the Company or the good order of the General Meeting that the question be answered. Shareholders who wish to listen to the business of the meeting by an audio dial-in facility will not be able to ask questions.

17. You may not use any electronic address (within the meaning of Section 333(4) of the CA 2006) provided in either this Notice or any related documents (including the form of proxy) to communicate with the Company for any purposes other than those expressly stated.

18. A copy of this Notice, and other information required by Section 311A of the CA 2006, can be found on the Company's website at www.futuramedical.com.